50th week of 2015 patent applcation highlights part 9 |
Patent application number | Title | Published |
20150352114 | MITOTIC KINESIN Eg5 INHIBITING ANTICANCER AGENTS - A method of treating glioblastoma multiforme (GBM) in a subject in need thereof including administering to the subject a therapeutically effective amount of an Eg5 inhibitor. | 2015-12-10 |
20150352115 | COMPOUNDS USEFUL FOR TREATING INJURIES FROM WARFARE AGENTS - Compounds and compositions for treating disorders related to TRPA1 are described herein. | 2015-12-10 |
20150352116 | HDAC INHIBITOR AND BTK INHIBITOR COMBINATIONS - Disclosed herein are methods and compounds for treating an individual diagnosed with chronic lymphocytic leukemia (CLL) or acute myeloid leukemia (AML) by administering to the individual a combination comprising ibrutinib and Abexinostat. Also provided are methods for treating an ibrutinib-resistant CLL or an ibrutinib-resistant AML by administering to the individual a combination comprising ibrutinib and Abexinostat. Further provided are methods of reducing the development of ibrutinib resistance in an individual having either CLL or AML or preventing the development of ibrutinib resistance in an individual having CLL or AML by administering to the individual a combination comprising ibrutinib and Abexinostat. | 2015-12-10 |
20150352117 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof. | 2015-12-10 |
20150352118 | EYE DROP COMPOSITION - The present invention relates to an eye-drop composition comprising 2-amino-9-[[(1S,2R)-1,2-bis(hydroxymethyl)cyclopropyl]methyl]-1,9-dihydro-6H-Purin-6-one, and the use thereof for the diagnosis and treatment of herpetic eye infections in companion animals. | 2015-12-10 |
20150352119 | SUBSTITUTED BENZENE COMPOUNDS - The present invention relates to substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. | 2015-12-10 |
20150352120 | USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING HYPOMAGNESEMIA, NEUROGENIC INFLAMMATION, AND CARDIAC DYSFUNCTION ASSOCIATED WITH EGFR-BLOCKING DRUGS - The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist. | 2015-12-10 |
20150352121 | COMBINATION - A novel combination comprising the PI3K-β inhibitor 2-methyl-1-{[2-methyl-3-(trifluoromethyl)phenyl]methyl}-6-(4-morpholinyl)-1H-benzimidazole-4-carboxylic acid, or a pharmaceutically acceptable salt thereof, with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of PI3K-β and/or B-Raf is beneficial, eg. cancer. | 2015-12-10 |
20150352122 | Novel Formulation of Meloxicam - Unit dosage forms of meloxicam containing either 5 mg or 10 mg of meloxicam that provide effective pain relief and have desirable pharmacokinetic properties are described. The unit dosage forms can provide pain relief when a single unit dose is administered to a patient and useful for treating pain such as osteoarthritis pain at a relatively low systemic exposure to meloxicam. | 2015-12-10 |
20150352123 | USE OF CAPSAZEPINE AND ANALOGS THEREOF TO TREAT CANCER - Disclosed are methods and compositions for treating cancer, particularly for reducing cancerous cell growth, for example, in solid tumors. Disclosed methods and compositions include capsazepine (CPZ) or an analog of CPZ. Compositions comprising CPZ or an analog of CPZ may be useful for simultaneously treating cancer and alleviating pain by blocking TRPV1 channels. | 2015-12-10 |
20150352124 | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND THERAPEUTIC USES THEREOF - The present invention relates to therapeutic uses of the compounds of formula (I): | 2015-12-10 |
20150352125 | Methods and Compositions for Treating Trauma-Hemorrhage Using Estrogen and Derivatives Thereof - Disclosed are methods and materials for treating or preventing complications due to traumatic injuries using estrogen or derivatives thereof. | 2015-12-10 |
20150352126 | NATURAL COMBINATION HORMONE REPLACEMENT FORMULATIONS AND THERAPIES - Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone. | 2015-12-10 |
20150352127 | INHALATION PARTICLES COMPRISING A COMBINATION OF AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC - Microparticles comprising a combination of an anticholinergic, a beta | 2015-12-10 |
20150352128 | CONTROLLED RELEASE AND TASTE MASKING ORAL PHARMACEUTICAL COMPOSITION - Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. | 2015-12-10 |
20150352129 | ASPIRIN FORMULATION FOR INCREASED EFFICACY - Provided are methods for enhancing the efficacy of aspirin. Also provided are methods for reducing pain or preventing or treating heart attack, stroke or blood clot in a subject in need thereof. The methods entail orally administering to the subject a first composition comprising a first amount of aspirin, and a second composition comprising a second amount of aspirin, wherein the first composition is formulated so as to, upon administration, disintegrate or dissolve intraorally providing rapid release of the aspirin of the first composition in the subject, and wherein the second composition is formulated to be substantially more difficult than the first composition to disintegrate or dissolve intraorally but is ingestible and releasable in the gastrointestinal track of the subject. The method can further include administering to the subject a painkiller or an agent suitable for treating a cardiovascular disease or condition. | 2015-12-10 |
20150352131 | Compositions and Methods for the Prevention and Treatment of Osteolysis and Osteoporosis - This application discloses compositions, devices, and methods for the prevention and treatment of osteolysis and osteoporosis. Treatment or prevention of osteolysis or osteoporosis is carried out by targeting the enzyme, Shp2 (a Src homology 2 (SH2) domain containing non-transmembrane Protein Tyrosine Phosphatase (PTP)), or proteins involved in the Shp2 signaling pathway by administering a Shp2 pathway inhibitor that inhibits fusion of pre-osteoclasts. | 2015-12-10 |
20150352132 | THERAPEUTIC AGENT FOR DEMYELINATING DISEASE - It is an object of the present invention to provide a novel therapeutic agent for demyelinating disease which has an action to suppress demyelination of nerve axons. According to the present invention, a therapeutic agent for demyelinating disease which comprises cyclic phosphatidic acids, carba-cyclic phosphatidic acids, thia-cyclic phosphatidic acids, or a salt thereof is provided. | 2015-12-10 |
20150352133 | SYNTHETIC OR RECOMBINANT FUCOSYLATED OLIGOSACCARIDES FOR USE IN THE TREATMENT OF INFECTIONS - The present invention relates to synthetic fucosylated oligosaccharide for use in the treatment or prophylaxis of an infection with a Norwalk-like Virus or Rotavirus of a mam-mal, wherein the synthetic fucosylated oligosaccharide comprises a non-reducing end and an reducing end, wherein the reducing end comprises a first carbohydrate unit consisting of a galactose (Gal) linked via a β1-4 glycosidic bond to a glucose (Glc), and wherein the non-reducing end comprises a second carbohydrate unit linked via a β1-3 glycosidic bond to the first carbohydrate unit of the reducing end, and wherein the second carbohydrate unit comprises a) at least one or more of a fucose (Fucose) and a Galactose (Gal), and b) at least one or more of a N-acetylglucosamine (GlcNAc) or a N-acetylgalactosamine (GalNAc). | 2015-12-10 |
20150352134 | COMPOSITION FOR TOPICAL SKIN APPLICATION CONTAINING GINSENOSIDE F2 DERIVED FROM HYDROPONIC GINSENG - Beneficial effects are obtained by topically applying ginsenoside F2 to the skin to improve skin conditions, improve water content on the skin surface and related benefits improving skin problems associated with acne or atopy, providing a skin whitening effect, helping control of sebaceous secretion, tightening skin pores, or improving skin complexion through enhanced blood circulation, but also to improve scalp and hair conditions, such as providing an anti-dandruff effect, promoting hair growth, or preventing generation of grey hair. | 2015-12-10 |
20150352135 | GLA Monotherapy for Use in Cancer Treatment - The present disclosure relates generally to compositions and methods for treating cancer with a glucopyranosyl lipid A (GLA) in the absence of antigen. | 2015-12-10 |
20150352136 | NOVEL AMINOGLYCOSIDES AND USES THEREOF IN THE TREATMENT OF GENETIC DISORDERS - A new class of paromomycin-derived aminoglycosides, which exhibit efficient stop-codon mutation suppression activity, low toxicity and high selectivity towards eukaryotic cells are provided. Also provided are chemical and chemo-enzymatic processes of preparing these paromomycin-derived aminoglycosides and intermediates thereof, as well as pharmaceutical compositions containing the same, and uses thereof in the treatment of genetic disorders. | 2015-12-10 |
20150352137 | THYMIDINE FOR PREVENTING NEURAL TUBE DEFECTS - The present invention relates to the prevention of neural tube defects. In particular, the invention provides thymidine or dTMP for use in a method of preventing or prophylactically treating a neural tube defect. The method may comprise administering the thymidine or dTMP to a female mammal that is pregnant or that may become pregnant. The thymidine or dTMP may be administered in combination with one or more purine molecules. | 2015-12-10 |
20150352138 | Polyvalent RNA-Nanoparticle Compositions - The present invention concerns nanoparticles functionalized with duplex RNA for a variety of uses, including but not limited to gene regulation. More specifically, the disclosure provides a new strategy for conjugating RNA to a nanoparticle to achieve increased stability and activity. | 2015-12-10 |
20150352139 | COMBINATION OF ANTICHOLESTEROLEMIC FIBER - The present invention relates to fiber compositions comprising fiber derived from onion and soluble fiber. Additionally, the invention relates to food products comprising said fiber compositions. In another aspect, the invention relates to methods for obtaining said fiber compositions as well as to the cosmetic uses and therapeutic uses thereof in the treatment and/or prevention of metabolic diseases, colon cancer and bowel inflammation. | 2015-12-10 |
20150352140 | BIOMASS-BASED DIETARY SUPPLEMENT - A biomass-derived dietary supplement comprising an acetate salt, a hemicellulose-derived sweetener, and cellulose is provided. The formulation may originate from treatment of biomass, by converting acetic acid (from biomass) to an acetate salt and combining it with a hemicellulose-based sweetener such as xylitol and inert, non-digestive cellulose. This is formed into a powder, crystal, pill or capsule to be delivered orally as a dietary supplement. Supplemental minerals and vitamins may be added. A process for producing a biomass-derived dietary supplement is also disclosed. | 2015-12-10 |
20150352141 | ATOPIC-DERMATITIS-SUPPRESSING FIBER, FIBER ASSEMBLY AND FIBER PRODUCT, METHOD FOR USING SAME, AND METHOD FOR SUPPRESSING ATOPIC DERMATITIS - The present invention relates to an atopic dermatitis suppressing fiber to which a compound containing a phosphate group is fixed by chemical bonding. The present invention further relates to an atopic dermatitis suppressing fiber assembly that includes the atopic dermatitis suppressing fiber arranged to contact skin. The present invention further relates to an atopic dermatitis suppressing fiber product that includes the atopic dermatitis suppressing fiber arranged to contact skin. The present invention further relates to a method for using the atopic dermatitis suppressing fiber and a method for suppressing atopic dermatitis that include: arranging the atopic dermatitis suppressing fiber to contact skin, thereby suppressing atopic dermatitis. | 2015-12-10 |
20150352142 | STABILIZED COMPOSITIONS COMPRISING HYALURONIC ACID - Provided herein are hyaluronic-acid based compositions comprising a hyaluronic acid-based polymer and a corticosteroid in the presence of a stabilizing amount of one or more stabilizing additives and related methods. The resulting compositions substantially retain their viscoelastic and related rheolotical properties under conditions of storage, processing, and use. | 2015-12-10 |
20150352143 | INJECTABLE FORMULATION OF NATURAL POLYSACCHARIDE AND POLYOL FOR TREATMENT OF OSTEOARTHRITIS - A sterile injectable aqueous formulation in the form of a gel made up of hyaluronic acid or a salt thereof and one or more polyols is provided. The gel formulation can be applied to the intra-articular area in the treatment of joint degeneration and osteoarthritis. The gel formulation has a rheology similar to that of synovial liquid and has an elevated resistance to degradation due to the synergistic action between the hyaluronic acid and the polyols. | 2015-12-10 |
20150352144 | USE OF ALGINATE COMPOSITIONS IN PREVENTING OR REDUCING LIVER DAMAGE CAUSED BY A HEPATOTOXIC AGENT - Disclosed herein are compositions, methods and uses utilizing alginate compositions, for treating, preventing and/or reducing liver damage induced by a hepatotoxic agent, and for treating a medical condition treatable by a hepatotoxic agent, in which an alginate composition is administered prior to, concomitant with, or shortly after exposure to a hepatotoxic agent. Also disclosed are pharmaceutical compositions comprising a hepatotoxic agent and an alginate composition and uses thereof for treating medical conditions treatable by the hepatotoxic agent. | 2015-12-10 |
20150352145 | Method and System for Treatment of Damaged Biological Tissue - Biomaterial compositions and articles comprising extracellular matrix (ECM) and an ECM-mimicking biomaterial, such as poly(glycerol sebacate) (PGS), for treating damaged biological tissue; particularly, damaged cardiovascular tissue. The biomaterial compositions and articles can also include additional biologically active agents, such as growth factors, and polymeric materials, such as polyepsilon-caprolactone (PCL). | 2015-12-10 |
20150352146 | MULTI-COMPONENT PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME - In accordance with one aspect of the invention, novel compositions containing injectable particles are provided in which the injectable particles contain at least two polymeric components that differ in composition from one another (e.g., because at least one polymeric component contains a polymer that is not present in another polymeric component). | 2015-12-10 |
20150352147 | Performance enhancing composition and use thereof - The performance of a mammal, manifested as a reduced oxygen uptake (VO | 2015-12-10 |
20150352148 | METHODS FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY EXTRACELLULAR MICROORGANISMS, INCLUDING ANTIMICROBIAL-RESISTANT STRAINS THEREOF, USING GALLIUM COMPOUNDS - The present invention relates to methods for preventing or treating infectious diseases caused by extracellular microorganisms, such as bacteria and fungi, by systemically administering to a patient a compound containing gallium. The extracellular microorganisms targeted by the present methods include methicillin-resistant | 2015-12-10 |
20150352149 | METHOD FOR STIMULATING RETINAL RESPONSE USING PHOTOACTIVE DEVICES - An improved method for stimulating electrical activity in an eye is provided. Provided is a technique for implanting small, nanometer-sized photoactive devices into an eye to improve electrical activity within an eye or mitigate degradation of electrical response in damaged eyes. | 2015-12-10 |
20150352150 | ORALLY ADMINISTERED ADSORBENT, THERAPEUTIC AGENT FOR RENAL DISEASE, AND THERAPEUTIC AGENT FOR LIVER DISEASE - An object of the present invention is to provide surface-modified spherical activated carbon exhibiting excellent adsorption capacity for uremic substances in the body, and particularly -aminoisobutyric acid. | 2015-12-10 |
20150352151 | ACTIVATED LEUKOCYTE COMPOSITION AND USES FOR WOUND HEALING - Disclosed are therapeutic, blood-derived activated leukocyte compositions, methods of making them, and methods of using the compositions to repair or promote the prevention and healing of wounds. | 2015-12-10 |
20150352152 | FLUID ASSOCIATED WITH ADULT STEM CELLS FOR MEDICAL, COSMETIC, AND VETERINARY USE - Apparatus and process to create, expand, and localize the population of stem cells in adult tissues by placing a foreign body either in omentum or in the subcutaneous tissue. The apparatus 1) traps the granulation fluid, cells a fluid rich in a myriad of growth factors, 2) mobilizes and concentrates free-floating stem cells in the granulation fluid and 3) stimulates the growth of a new tissue around the apparatus, which provides another source of stem cells. Stem cells obtained by this process can be used as freshly isolated or after culturing, which can be used for wound healing, treating diseases, and regenerating organs in animals and humans. The granulation fluid could substitute the stem cells in many of their applications and offers the convenience of an injectable medicine for treating animal and human diseases | 2015-12-10 |
20150352153 | REPAIR OF PERIPHERAL NERVE INJURY - The invention relates to methods and compositions for maintaining the pro-regenerative capacity of distal nerve segments following nerve injury. | 2015-12-10 |
20150352154 | INDUCED PLURIPOTENT CELL-DERIVED OLIGODENDROCYTE PROGENITOR CELLS FOR THE TREATMENT OF MYELIN DISORDERS - The present invention relates to preparations of induced pluripotent cell-derived oligodendrocyte progenitor cells, and methods of making, isolating, and using these preparations. | 2015-12-10 |
20150352155 | USE OF ANTI-AGING GLYCOPEPTIDES TO ENHANCE PANCREATIC CELL HEALTH, SURVIVAL AND IMPROVE TRANSPLANT OUTCOME - The present disclosure relates to an in vitro method for enhancing engraftment of isolated pancreatic cells comprising the step of contacting an isolated pancreatic cell prior to a transplantation in a subject in need thereof, with a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I: | 2015-12-10 |
20150352156 | GROWTH FACTOR SEQUESTERING AND PRESENTING HYDROGELS - Provided herein are hydrogel cell matrices, hydrogel cell matrix systems for the support, growth, and differentiation of a stem cell or progenitor cell and methods for making such hydrogel cell matrices. | 2015-12-10 |
20150352157 | Wound Dressing Nanomesh Impregnated with Human Umbilical Cord Wharton's Jelly Stem Cells - The invention is directed to a method of treating a wound (e.g., to suppress scar formation) in an individual in need thereof comprising contacting the wound with an effective amount of a composition comprising (i) Wharton's jelly stem cells (WJSCs). (ii) a cell culture medium that has been conditioned with WJSCs. (iii) a lysate of WJSCs. (iv) a cell culture medium that has been conditioned with WJSCs exposed to apoptotic skin cells and keloid cells, or (v) a combination thereof. The invention is directed to a medical dressing (e.g., pharmaceutical compositions) comprising Wharton's jelly stem cells (WJSCs), a cell culture medium that has been conditioned with WJSCs, a lysate of WJSCs, a cell culture medium that has been conditioned with WJSCs exposed to apoptotic skin cells and keloid cells, or a combination thereof. | 2015-12-10 |
20150352158 | Method and preparation for accelerating fracture healing - The invention relates to medicine and can be used for accelerating the healing of bone fractures. The claimed invention is directed to solving the technical problem of accelerating fracture healing and reducing patient rehabilitation times and periods of incapacity for work. | 2015-12-10 |
20150352159 | Method and preparation for treating arthritis and arthrosis - The present method and preparation for treating arthritis and arthrosis relates to medicine, and more particularly to methods for controlling arthritis and arthrosis. The method is implemented by filling cavity lesions in the bone tissue and consists in providing to the body a supply of drone brood in conjunction with a supply of calcium. | 2015-12-10 |
20150352160 | THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING INFECTIONS - This disclosure describes, in one aspect, a composition that includes a transgenic pathogen that expresses a heterologous pathogen associated molecular pattern (PAMP). In some embodiments, the pathogen may be attenuated. In some embodiments, the pathogen can include | 2015-12-10 |
20150352161 | USE OF HAFNIA ALVEI FOR REDUCING THE CARRIAGE OF ESCHERICHIA COLI PRODUCING SHIGA TOXINS (STEC) IN RUMINANTS - The invention relates to a method for reducing the risk of contamination of milk and meat when milking and slaughtering ruminants carrying STEC. The invention especially relates to a method for reducing the carriage of STEC by ruminants, characterised by the administration of at least one strain of | 2015-12-10 |
20150352162 | BABY FOOD COMPOSITION COMPRISING VIABLE PROPIONIC ACID-PRODUCING BACTERIA - The present invention relates to compositions, particularly baby food compositions, comprising living lactate-utilizing propionic acid-producing bacteria, as well as viable lactic-acid producing bacteria, its manufacture and use in the treatment of digestive diseases, particularly for treatment of infantile colic, intestinal discomfort, intestinalpain, visceral sensitivity, and intestinal cramp. | 2015-12-10 |
20150352163 | EDIBLE PRODUCTS HAVING A HIGH COCOA POLYPHENOL CONTENT AND IMPROVED FLAVOR AND THE MILLED COCOA EXTRACTS USED THEREIN - Milling dry extracts containing cocoa polyphenols (CPs) to reduce the particle size improves the flavor of edible products (e.g., foods, medical foods, nutritional supplements, and pharmaceuticals) or additives containing the milled cocoa extracts. The products, e.g., chocolates, are less astringent and less bitter. The mean particle size after milling is less than about 15 microns, preferably less than about 10 microns, and most preferably less than about 5 microns. The total CP content of the milled extracts is at least about 300 milligrams and preferably about 300 to about 700 milligrams per gram of milled extract. The additives consist essentially of (i) the milled high CP cocoa extract and (ii) a fat (e.g., cocoa butter), an oil (e.g., vegetable oil), or a syrup (e.g., corn syrup). | 2015-12-10 |
20150352164 | COMPOSITION COMPRISING THEANINE AND AN EXTRACT OF INULA RACEMOSA - Edible composition comprising theanine and an extract of | 2015-12-10 |
20150352165 | CLINDAMYCIN PHOSPHATE, SALICYLIC ACID AND TEA TREE OIL COMBINATIONS - The present invention relates to the topical compositions comprising clindamycin phosphate, salicylic acid and tea tree oil; to the preparation methods thereof; and to the use thereof in the treatment of skin infections and acne vulgaris accompanied by inflammatory lesions. | 2015-12-10 |
20150352166 | Compositions for the Treatment of Dermatological Conditions, Disorders or Diseases - The present invention relates to compositions comprising black cumin ( | 2015-12-10 |
20150352167 | PHARMACEUTICAL OR FOOD COMPOSITION COMPRISING OLDENLANDIA BRACHYPODA, SPERGULARIA MARINA, DISPORUM SMILACINUM, PERSICARIA POSUMBU, OR GEUM ALEPPICUM - The present disclosure relates to a pharmaceutical composition or a food composition which has excellent activity of stimulating enteroendocrine cells while being safe with few side effects. The composition contains one or more of an | 2015-12-10 |
20150352168 | Pharmaceutical Composition for Treating Headache, and Preparation Method Thereof - A pharmaceutical composition for treating headache, prepared from eleven Chinese herbal medicines: Chinese angelica root, ligusticum chuanxiong, radix paeoniae lactiflorae, prepared rhizome of rehmannia, uncaria tomentosa, leatherleaf milletia, prunella vulgaris, sicklesenna seed, pearl shell, corydalis tuber, and asarum, and a proper amount of adjuvant materials. A preparation method of the pharmaceutical composition, and uses thereof in the preparation of drugs for treating various headaches, traumatic cranial nerve syndrome, dizziness and vertigo, vexation and irritability, insomnia and dreaminess. | 2015-12-10 |
20150352169 | COMPOSITIONS COMPRISING HEAT-TREATED CLEAR TOMATO CONCENTRATE - The present invention provides a therapeutic composition comprising heat-treated clear tomato concentrate (CTC), which has been found to possess both anti-inflammatory and bone-health promoting effects. The present invention is also directed to a composition comprising heat-treated CTC in combination with one or more carotenoids. | 2015-12-10 |
20150352170 | Palm Pollen for Treatment of Mucositis and Inflammatory Conditions - Compositions are provided that include date palm pollen or an extract thereof. The compositions may be formulated use in methods of treatment or prophylaxis of inflammatory conditions such as adverse side effects of anti-cancer treatment or stomatitis conditions. | 2015-12-10 |
20150352171 | Herpes Treatment - Various human diseases, including herpes, antibiotic resistant bacterial infections, cutaneous Leishmaniasis, malaria and multiple sclerosis can be treated with injections of garlic juice. The garlic juice is produced by cutting, crushing, or otherwise damaging garlic cloves, and collecting the juice. This garlic juice is dissolved in a carrier solution, such as water or saline, and then injected into the patient. | 2015-12-10 |
20150352172 | SYNERGISTIC DIETARY SUPPLEMENT COMPOSITIONS FOR ENHANCING PHYSICAL PERFORMANCE AND ENERGY LEVELS - The present invention discloses novel synergistic dietary supplement compositions comprising at least two ingredients selected from the extracts and fractions derived from | 2015-12-10 |
20150352173 | INSTANT WATER SOLUBLE BIOACTIVE DIETARY PHYTONUTRIENTS COMPOSITION OF SPICE/HERB EXTRACTS AND A PROCESS FOR ITS PREPARATION - The present invention relates to a method for the preparation of the instant water soluble, stable, phytonutrient rich spice/herb extracts exhibiting significant antioxidant and other bioactivities, in a ready to use form and a composition for beverage and food applications to deliver physiologically relevant amounts of phytonutrients per serving without taste or aroma issue and in organic quality. The composition derived in the present invention include the bioactive phytonutrient molecules along with its natural counter parts comprising mainly proteins, carbohydrates and dietary fibre of the spice and/or herb. | 2015-12-10 |
20150352174 | USE OF GLYCYL GLUTAMINE AGAINST DEPRESSION - A prophylactic or therapeutic agent is provided for depression (including each subtype according to DSM-IV of depression) or anxiety by increasing the levels of serotonin in the brain includes administration of glycyl-glutamine or cyclo glycyl-glutamine, a derivative that could cross the blood-brain barrier and could be used in peripheral applications. | 2015-12-10 |
20150352175 | TREATMENT OF DEGENERATIVE JOINT DISEASE - The invention provides a method of treating a degenerative joint disease. The method comprises administering an effective amount of a pharmaceutical composition comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP). The invention also provides a pharmaceutical product as well as a kit comprising DA-DKP. | 2015-12-10 |
20150352176 | OIL-FREE AND FAT-FREE AQUEOUS SUSPENSIONS OF CYCLOSPORIN - Compositions that are oil-free and fat-free aqueous suspensions of cyclosporin and contain a cyclosporin (e.g., cyclosporine), a hydrophilic pharmaceutically acceptable solvent in which the cyclosporin (e.g., cyclosporine) is soluble, a dispersing agent, a suspending agent and an aqueous vehicle are disclosed. Methods of producing such compositions, as well as methods of using the compositions to treat ophthalmic disorders are also disclosed. | 2015-12-10 |
20150352177 | Method Of Treating An Ocular Disease And Compositions Effective For Treating An Ocular Disease - Methods and compositions are provided for treating an ocular disease in a subject in need thereof by increasing the bioavailability of a drug in the subject's eye. In one aspect, the ocular disease is at least one of diabetic retinopathy, macular degeneration, endopthalmitis, glaucoma, cataracts, ocular herpes. The methods and compositions provided herein include an efflux transporter inhibitor and a drug effective for treating the ocular disease. The efflux transporter inhibitor is effective to reduce the efflux of the drug through at least one of P-glycoprotein (Pgp), breast cancer resistant protein (BCRP), and multidrug resistant associated protein 1-9 (MRP1-9). | 2015-12-10 |
20150352178 | LOW PROTEIN INFANT FORMULA WITH INCREASED ESSENTIAL AMINO ACIDS - The present invention concerns an improved balance of the essential branched chain amino acids leucine, isoleucine and valine in infant formula. | 2015-12-10 |
20150352179 | COMPOSITIONS AND METHODS INVOLVING ENDOGENOUS RETROVIRUS PROTEINS - This disclosure describes methods and compositions that involve endogenous retrovirus proteins as diagnostic markers and/or therapeutic agents. The detection of endogenous retrovirus envelope proteins on a cell surface can indicate early neoplasticity of the cell. Antibody compositions that specifically bind to cell-surface-expressed endogenous retrovirus proteins may be used in such diagnostic methods. Overexpression of the endogenous retrovirus proteins can slow cell growth and decrease cell viability. | 2015-12-10 |
20150352180 | Notch Ligand Bound Biocompatible Substrates And Their Use In Bone Formation - Disclosed herein are compositions comprising an osteoinductive Notch ligand bound to at least one biocompatible substrate. Also disclosed are methods of treating patients in need of bone tissue formation through the administration of a composition comprising an osteoinductive Notch ligand bound to at least one biocompatible substrate. Further provided are methods of treating a patient in need of bone tissue formation comprising administering to said patient a composition comprising a nucleic acid molecule encoding a notch intracellular domain (NICD). Also disclosed are kits for promoting bone tissue formation. | 2015-12-10 |
20150352181 | METHODS FOR TREATING TISSUE DAMAGE ASSOCIATED WITH ISCHEMIA WITH APOLIPOPROTEIN D - The invention provides methods for treating tissue damage associated with impaired blood flow using ApoD, or an active variant thereof, or an agent that increases the expression of ApoD. The invention also encompasses active variants of ApoD for use in the methods. | 2015-12-10 |
20150352182 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE CARDIOPROTECTION - The present invention relates to methods and pharmaceutical compositions for cardioprotection of subjects who experienced a myocardial infarction. In particular, the present invention relates to a ligand of the sonic hedgehog signaling pathway for use in the cardioprotection of a subject who experienced a myocardial infarction. | 2015-12-10 |
20150352183 | LAMININS, DERIVATIVES, AND COMPOSITIONS INCLUDING SAME AND METHODS FOR THEIR THERAPEUTIC USE - In various embodiments, the present disclosure provides a method of treating a subject using laminin or a composition that includes laminin. In one embodiment, the method is used to enhance muscle regeneration, maintenance, or repair in a subject. In another embodiment, the method is used to promote wound healing. The method, in yet another embodiment, is used to prevent or reduce muscle damage or injury. In specific implementations of these methods, the laminin or composition that includes laminin is administered in a therapeutically effective amount. In some implementations, the laminin is a complete laminin protein. In other implementations, the laminin is a laminin fragment, a laminin derivative, or a laminin analogue. | 2015-12-10 |
20150352184 | METHOD AND COMPOSITIONS FOR GENETIC AND RETINAL DISEASE - An inventive method for treatment or prevention of vascular diseases of the retina is provided. A Norrin compound is optionally administered to a subject either directly and/or as expressed by a cell. The presence of the compound is either protective of or therapeutic for a pathological condition of the retina. Preferred pathological conditions are those linked to the absence of or mutation of norrin protein and are preferably Norrie disease, FEVR, or macular degeneration. | 2015-12-10 |
20150352185 | METHOD FOR INCREASING NEPRILYSIN EXPRESSION AND ACTIVITY - This invention is directed to methods and compositions for increasing the expression or activity of neprilysin in, for example, the frontal cortex or the entorhinal cortex using a progranulin polypeptide or effector. The present invention is further directed to methods of reducing microglia in the brain of a patient with neurodegenerative disease using a progranulin polypeptide or effector. | 2015-12-10 |
20150352186 | FACTOR 1 PROTEIN, FACTOR 2 PROTEIN AND INHIBITORS THEREOF FOR USE IN TREATING OR PREVENTING DISEASES - The present invention relates to proteins comprising amino acid sequences encoded by nucleic acids derived from the human chromosomal region C19Orf10 termed Factor1 and/or C19Orf63 termed Factor 2 for the use in enhancing proliferation and/or healing and/or inhibiting apoptosis of none-transformed tissue or none-transformed cell or inhibitors thereof. The invention further relates to the use of inhibitors of factor1 and factor 2 for medical use, preferably for use in treating or preventing a disease in which angiogenesis contributes to disease development or progression. | 2015-12-10 |
20150352187 | COMPOSITION HAVING TISSUE-REPAIRING ACTIVITY, AND USE THEREFOR - A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan. | 2015-12-10 |
20150352188 | METHODS AND COMPOSITIONS FOR TREATMENT OF BONE, SKIN, SUBCUTANEOUS, MUCOSAL AND/OR SUBMUCOSAL CANCER BY PERCUTANEOUS AND/OR TRANSMUCOSAL ADMINISTRATION OF INTERFERON - The invention provides a method and/or composition for the treatment of bone cancer including primary bone cancer and secondary bone cancer, breast cancer, skin cancer, nasopharyngeal carcinoma, oral cancer, vulva cancer, prostate cancer, cervical cancer, melanoma including melanocarcinoma by percutaneous and/or transmucosal administration of the interferon. Further, the invention provides a method and/or composition for the treatment of skin, subcutaneous, mucosal and/or submucosal primary cancer and cancer metastatic lesions by percutaneous and/or transmucosal administration of the interferon, especially a method and/or composition for the treatment of bone cancer pain including pain resulted by secondary bone cancer. | 2015-12-10 |
20150352189 | ACTIVATION OF THE ENDOGENOUS ILEAL BRAKE HORMONE PATHWAY FOR ORGAN REGENERATION AND RELATED COMPOSITIONS, METHODS OF TREATMENT, DIAGNOSTICS, AND REGULATORY SYSTEMS - In one embodiment, the invention provides a method of regenerating organs and tissues in a subject suffering from one or more organ or tissue manifestations of glucose supply side associated metabolic syndrome, the method comprising: (a) confirming that the subject suffers from or is at risk for suffering from organ and/or tissue damage associated with a glucose supply side associated metabolic syndrome; and (b) co-administering to the subject an effective amount of a pharmaceutical composition comprising a first and optionally a second active composition, said first active composition comprising an ileal brake hormone releasing substance encapsulated within an enteric coating which releases said substance within said subject's ileum and ascending colon causing release of at least one ileal brake hormone from L-cells of said subject, said optional second active composition being formulated in immediate and/or early release form in an over coating onto said enteric coating, wherein said second composition is beneficial to at least one aspect of said subject's metabolic syndrome manifestations. Coadministration methods with a second pharmaceutical composition are also disclosed. | 2015-12-10 |
20150352190 | Modified Factor VIII - Methods of treating patients with Factor VIII deficiency by administration of modified porcine factor VIII are disclosed. The particular modified porcine factor VIII is one in which most of the B domain has been removed through genetic engineering. This modified factor VIII is particularly useful for treatment of hemophiliacs, especially those undergoing bleeding episodes. | 2015-12-10 |
20150352191 | TREATMENT OF SKIN DISORDERS - The present invention is based upon the finding that certain conditions, diseases and/or disorders affecting the skin, are associated with reduced expression of an enzyme exhibiting oxidoreductase activity. Accordingly, the invention provides oxidoreductase enzymes and/or genes encoding the same for use in treating or preventing disorders of the skin and method for generating Type VII collagen suitable for use in treating disorders of the skin. | 2015-12-10 |
20150352192 | METHODS AND COMPOSITIONS FOR TREATING CANCER - A method of treating cancer in a subject includes administering to the subject a therapeutically effective amount of an agent that specifically binds to or complexes with a proteolytically cleaved extracellular fragment of an immunoglobulin (Ig) superfamily cell adhesion molecule (CAM) or its receptor that is expressed by a cancer cell or another cell in the cancer cell microenvironment. The agent inhibits the cell adhesion function of the cleaved extracellular fragment or its receptor. | 2015-12-10 |
20150352193 | SELECTIVE GLYCOSIDASE REGIMEN FOR IMMUNE PROGRAMMING AND TREATMENT OF CANCER - The present invention relates to treatment and prevention of cancer with glycosidase(s). In various aspects the invention relates to the treatment and management of cancer to prevent metastasis or recurrence, or to improve outcome and rate of successful treatment with conventional therapeutic regimens. | 2015-12-10 |
20150352194 | INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR XA DERIVATIVES - The present disclosure relates to compositions and methods for the treatment of bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand (vWF) disease, and factor XII deficiency, by reducing the circulating concentration of tissue factor pathway inhibitor (TFPI), with a factor Xa derivative. | 2015-12-10 |
20150352195 | Methods and Pharmaceutical Compositions for Treating Celiac Disease and Gluten Intolerance - Oral administration of ALV003 can protect celiac disease patients and patients otherwise suffering from gluten-intolerance from the harmful effects of ingesting food containing gluten. | 2015-12-10 |
20150352196 | Methods and Pharmaceutical Compositions for Prevention of Aging-Related Lesions - The present invention relates to methods and compositions for prevention of aging-related lesions. More particularly, the present invention relates to a calpain inhibitor compound for use in a method for preventing aging-related lesions in a subject in need thereof. | 2015-12-10 |
20150352197 | PEPTIDE - There is provided a peptide which is capable of binding to an MHC molecule in vitro and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises all or a portion of the following proteolipid protein (PLP) peptides: PLP 36-61: HE ALTGTEKLIET YF SKN YQD YEYLI (SEQ ID NO. 1) PLP 179-206: TWTTCQSIAFPSKTSASIGSLCA DARMY (SEQ ID NO. 2) PLP 207-234: GVLPWNAFPGKVCGSNLLSICKTAEFQM (SEQ ID NO. 3). There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide. | 2015-12-10 |
20150352198 | Method of Inducing And/Or Enhancing An Immune Response to Tumor Antigens - An improved method of inducing and/or enhancing an immune response to a tumor antigen is disclosed. The method involves administering the tumor antigen, nucleic acid coding therefor, vectors and/or cells comprising said nucleic acid, or vaccines comprising the aforementioned to a lymphatic site. | 2015-12-10 |
20150352199 | Dendritic Cells - The present invention relates to dendritic cell loaded with at least one nucleic acid molecule encoding a tumor associated antigen protein or fragment thereof and at least one tumor associated antigen protein or fragment thereof. | 2015-12-10 |
20150352200 | METHOD FOR PREPARING AN IMMUNOGENIC LYSATE, THE LYSATE OBTAINED, DENDRITIC CELLS LOADED WITH SUCH LYSATE AND A PHARMACEUTICAL COMPOSITION COMPRISING THE LYSATE OR THE DENDRITIC CELLS - The present invention relates to a method for the preparation of an immunogenic lysate from mesothelioma tumor cells, to such a lysate and to dendritic cells loaded with the lysate, the present invention further relates a pharmaceutical composition comprising such lysate or dendritic cells, to the use of the lysate, and to said loaded dendritic cells or said pharmaceutical composition for use in the prevention or treatment of mesothelioma. | 2015-12-10 |
20150352201 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF - This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein. | 2015-12-10 |
20150352202 | BROADLY REACTIVE MOSAIC PEPTIDE FOR INFLUENZA VACCINE - The invention provides for mosaic influenza virus HA and NA sequences and uses thereof. | 2015-12-10 |
20150352203 | SIMIAN ADENOVIRUS NUCLEIC ACID AND AMINO ACID SEQUENCES, VECTORS CONTAINING SAME, AND METHODS OF USE - A recombinant vector comprises simian adenovirus sequences and a heterologous gene under the control of regulatory sequences. A cell line which expresses simian adenovirus gene(s) is also disclosed. Methods of using the vectors and cell lines are provided. | 2015-12-10 |
20150352204 | BLOOD PLASMA BIOMARKERS FOR BEVACIZUMAB COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER - The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer, by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of E-selectin, ICAM-1 or VEGFR-3 relative to control levels of patients diagnosed with HER2 positive breast cancer, in particular locally recurrent or metastatic HER2 positive breast cancer. | 2015-12-10 |
20150352205 | ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS - The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat thrombosis in diseases associated with abnormal blood coagulation or fibrinolysis. In preferred embodiments these patients will comprise those exhibiting elevated D-dimer or other coagulation cascade related proteins and optionally will further exhibit elevated C reactive protein prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, et al. | 2015-12-10 |
20150352206 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER - In some embodiments, the methods involve the use of a combination of at least two of the following: an inhibitor of indoleamine-2,3-dioxygenase (IDO), an inhibitor of the PD-L1/PD-1 pathway, an inhibitor of CTLA-4, an inhibitor of CD25, or IL-7. The inventors particularly observed a major synergistic effect of combining anti-CTLA-4 with either an IDO inhibitor, with anti-PD-L1 mAb, or with CD-25 depletion. Such combinations have been found to demonstrate a synergistic effect in treating cancer and tumors, for example by reducing tumor size, increasing the percentage of antigen-specific T cells, and increasing T cell function. | 2015-12-10 |
20150352207 | USE OF ANTIBODIES AGAINST ICAM-1 IN COMBINATION WITH AN ANTI CANCER DRUG IN THE TREATMENT OF PATIENTS - There is provided antibodies or antigen-binding fragments thereof with binding specificity for ICAM-1, together with further anti-cancer agents, and compositions thereof, for use in the treatment of cancer. | 2015-12-10 |
20150352208 | INHIBITION OF CXCR4 SIGNALING IN CANCER IMMUNOTHERAPY - The inventions describes a method for increasing effector T cell accumulation in cancer cell-containing sites of a tumor, comprising administering to a subject in need thereof a pharmaceutically effective amount of an inhibitor of CXCR4 signaling. | 2015-12-10 |
20150352209 | NANOFIBER HAVING SELF-HEATING PROPERTIES AND BIOLOGICALLY ACTIVE SUBSTANCE RELEASE PROPERTIES, PRODUCTION METHOD FOR SAME, AND NONWOVEN FABRIC HAVING SELF-HEATING PROPERTIES AND BIOLOGICALLY ACTIVE SUBSTANCE RELEASE CAPABILITIES - The invention aims to provide a nanofiber having self-heating properties and biologically active substance release properties, which can release a drug at the same time as self-heating, and can be safely used on a human body without diffusing self-heating nanoparticles, a production method for the same, and a nonwoven fabric having self-heating properties and biologically active substance release capabilities. A fiber is provided having a diameter in a range of 50 nm to 50 μm, and a length of 100 times the diameter or more, the fiber including: self-heating particles that generate heat in response to stimulation from outside; a stimulation-responsive polymer of which physical properties change by directly or indirectly reacting due to the stimulation; and a biologically active substance that is held by the stimulation-responsive polymer, in which the biologically active substance is released to the outside in response to the changes in the physical properties of the stimulation-responsive polymer, a production method for the same, and a nonwoven fabric having self-heating properties and biologically active substance release capabilities. | 2015-12-10 |
20150352210 | PARTICLE FUNCTIONALIZATION - Particle functionalization systems including one or more of: a target of a material; an energetic ion and/or electron source providing accelerated ions and electrons to the target; a potential that is applied to at least the target and that causes ions and/or electrons from the ionized gas to impact a surface of the target and release atoms of the material; at least one magnet providing a magnetic field that controls movement of the ions and electrons and nucleation, formation and growth of particles from the released atoms; and a particle collection device that collects particles, the collection device comprising a substrate and a polymeric functionalization coating disposed on the substrate, wherein particles impinge upon and form bonds with molecules of the functionalization coating. Methods of preparing functionalized particles, functionalized particle compositions, and kits including functionalized particles are also described. | 2015-12-10 |
20150352211 | Implants for Administering Substances and Methods of Producing Implants - In some aspects, the invention relates to a porous implant, comprising a resorbable or bio-erodible porous silicon-based carrier material; a reservoir formed within the body of the porous silicon-based carrier material; and a beneficial substance disposed within the reservoir. | 2015-12-10 |
20150352212 | DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS - Disclosed herein are formulations containing carbidopa and optionally levodopa, arginine, and other components that have reduced levels of impurities and toxins, particularly degradation productions. Also disclosed herein are methods of treatment diseases or conditions relating to a loss of dopamine or dopaminergic neurons using such formulations, methods of making such formulations, and kits that include such formulations. | 2015-12-10 |
20150352213 | METHOD FOR TREATING PANCREATIC CANCER - A method for treating pancreatic cancer is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical formulation, wherein the pharmaceutical formulation comprises (Z)-butylidenephthalide and is substantially free of (E)-butylidenephthalide. | 2015-12-10 |
20150352214 | FUNCTIONAL STARCH POWDER - Functional starch powder of 400% or more water retention capacity, 5 hr or more collapse time and 200 g or more gel indentation load. | 2015-12-10 |